EGFR and non-small cell lung carcinoma: The investigation of new TKIs of fourth generation, such as mutant-selective allosteric inhibitors capable of simultaneously inhibiting sensitizing EGFR-mutations, T790M, and C797S (and similar resistant mutations), as well as targeted drug combinations capable of overcoming resistance to the currently used EGFR-TKIs and improving the outcome of specific subgroups of EGFRM+ NSCLC patients is ongoing [286,287].